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The radiation-attenuated Schistosoma mansoni vaccine is highly effective in rodents and primates but has
never been tested in humans, primarily for safety reasons. To strengthen its status as a paradigm for a human
recombinant antigen vaccine, we have undertaken a small-scale vaccination and challenge experiment in
chimpanzees (Pan troglodytes). Immunological, clinical, and parasitological parameters were measured in three
animals after multiple vaccinations, together with three controls, during the acute and chronic stages of
challenge infection up to chemotherapeutic cure. Vaccination induced a strong in vitro proliferative response
and early gamma interferon production, but type 2 cytokines were dominant by the time of challenge. The
controls showed little response to challenge infection before the acute stage of the disease, initiated by egg
deposition. In contrast, the responses of vaccinated animals were muted throughout the challenge period.
Vaccination also induced parasite-specific immunoglobulin M (IgM) and IgG, which reached high levels at the
time of challenge, while in control animals levels did not rise markedly before egg deposition. The protective
effects of vaccination were manifested as an amelioration of acute disease and overall morbidity, revealed by
differences in gamma-glutamyl transferase level, leukocytosis, eosinophilia, and hematocrit. Moreover, vacci-
nated chimpanzees had a 46% lower level of circulating cathodic antigen and a 38% reduction in fecal egg
output, compared to controls, during the chronic phase of infection.
Despite decades of intense efforts to control human schis-
tosomiasis, the disease is still one of the major health problems
in Africa and parts of South America and Asia. Although
education, improved sanitation, eradication of the snail vector,
and chemotherapeutic cure of infected patients are important
for reducing the prevalence and morbidity in areas of ende-
micity, only an effective vaccine can provide protection against
reinfection (7, 11, 68). Evidence in human populations for
natural resistance (63, 64) and acquired immunity against
schistosome infection (8, 20, 27) suggests that the development
of a vaccine is a realistic aim. As the parasites do not replicate
in the definitive host, even a partial reduction in worm burden
would be beneficial in reducing morbidity and transmission
(14). However, identification of relevant protective immune
mechanisms in humans is hampered by their continual expo-
sure to schistosome cercariae, uncertainties about the worm
burden acquired, the behavior and nutritional status of the
patients, and superinfection with other parasites (9, 25, 44, 61).
For these reasons, the approach has yet to provide a clear lead
for vaccine development.
More progress has been made using laboratory animal mod-
els, including nonhuman primates. The most effective and re-
producible protocol to date is vaccination with radiation-atten-
uated (RA) cercariae (15), which results in a 50 to 80%
reduction in challenge worm burden. Unlike the analogous
attenuated-sporozoite malaria vaccine (52), this schistosome
vaccine has not been tested in human volunteers, primarily for
reasons of safety (15), and such vaccines have generally proved
impractical for field use because of their brief shelf life. How-
ever, the RA vaccine could form a basis for a recombinant
vaccine, if the relevant immune mechanisms and protective
antigens were known (21). Thus, it is important to establish the
strongest possible probability that it would be effective in hu-
mans. Chimpanzees, which are genetically and physiologically
closest to humans, can become infected with schistosomes in
the wild (1, 51) and develop pathology indistinguishable from
that in human patients (35, 55, 56, 66), unlike rodents or other
primates. We have therefore undertaken a small-scale vacci-
nation and challenge experiment to test RA vaccine efficacy in
chimpanzees, taking advantage of the full range of immuno-
logical assays now available. The study has added value in
permitting a longitudinal investigation, in the control animals,
of the way in which immune responses to schistosomes evolve
through the acute to the chronic stage of infection. This is
impermissible in human subjects, even if the point of infection
were known, because of the ethical requirement to treat in-
fected individuals with chemotherapy upon diagnosis. We
demonstrate that chimpanzees can be protected against chal-
lenge infection with Schistosoma mansoni, manifested as an
amelioration of the acute disease as well as the overall mor-
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bidity, and a reduction in circulating cathodic antigen (CCA)
levels and egg burden compared to the control chimpanzees.
MATERIALS AND METHODS
Chimpanzees. The study was carried out using six unrelated healthy 5- to
6-year-old male chimpanzees (Pan troglodytes), selected randomly from the
breeding colony at the Biomedical Primate Research Center (BPRC). During
the entire experiment, the chimpanzees were housed in a social group of nine
animals. All protocols were approved by independent Scientific and Ethical
Committees at BPRC and the University of York. The study was performed in
compliance with the relevant laws relating to the conducting of animal experi-
ments and according to the recommendations and guidelines of the Primate
Vaccine Evaluation Network of the European Commission. The animals were
regularly monitored for abnormalities in the feces; changes in appetite and
behavior; and alterations in body temperature, weight, and general health status.
Sampling procedures were restricted to those which could be reasonably carried
out on human patients and were performed under intramuscular (i.m.) ketamine
sedation (except fecal sampling). At the end of this study, the chimpanzees were
cured and retired within the facilities at the BPRC.
Vaccination schedule. Cercariae of a Puerto Rican isolate of S. mansoni
(Department of Parasitology, Leiden University Medical Center) were irradiated
at a dose of 300 Gy using a 60Co source at the BPRC. The whole experimental
system was validated at the BPRC by a successful vaccination-challenge study in
C57BL/6 mice (data not shown). Three chimpanzees (V1, V2, and V3) were
anesthetized i.m. with an appropriate dose of tiletamine-zolazepam (Zoletil;
Virbac, Barneveld, The Netherlands). The vaccination and challenge regimen
was based on previous work in vervets and baboons, where three exposures
elicited approximately 50% protection (69, 70). The chimpanzees were exposed
to 9,000 attenuated cercariae in 10 ml of water, applied to the shaved abdominal
skin in stainless steel rings (diameter, 52 mm; height, 15 mm), for 30 min. The
vaccination procedure was repeated twice, 5 weeks and 10 weeks later, using a
different exposure site on the abdomen on each occasion. Three weeks after the
last immunization, the three vaccinated chimpanzees as well as three control
chimpanzees (C1, C2, and C3) were challenged on an equally carefully placed
site on the abdomen with 2,000 normal, i.e., nonattenuated cercariae, again
under tiletamine-zolazepam anesthesia. The dose of 2,000 challenge parasites
was chosen to provoke measurable secondary responses in the vaccinated group
but not excessive immunopathology in the infected control group, based upon
observations in humans with high-intensity infections in areas of endemicity (16).
Between week 28 and 36 postchallenge (p.c.), at different time points for the
individual chimpanzees based on clinical status, each was given an i.m. injection
of 40 mg of praziquantel (Droncit; Bayer, Mijdrecht, The Netherlands) per kg of
body weight on two successive days, in order to terminate the infection. In each
case, 1 mg of methylprednisolone (Solu-Medrol; Brocacef, Maarssen, The Neth-
erlands) per kg was administered i.m. 1.5 h prior to treatment in order to prevent
possible side effects such as abdominal cramping.
Preparation of antigens. Soluble adult worm antigens (SWAP), soluble larval
antigens (SLAP), and antigens released by schistosomula within the first 3 h after
transformation (0–3hRAP) were prepared as published elsewhere (43). Soluble
egg antigens (SEA) were obtained after homogenization of eggs by sonication
and pelleting the debris at 100,000 3 g for 60 min. Egg-secreted proteins (ESP)
were concentrated from the supernatant of eggs cultured in RPMI-1640 (Life
Technologies, Paisley, United Kingdom) supplemented with penicillin (300
U/ml), streptomycin (300 mg/ml), and gentamicin (500 mg/ml) for 72 h at 37°C in
5% CO2 (6). Recombinant His-tagged SmE16 (33, 42) was purified using
TALON affinity matrix (Clontech Laboratories, Basingstoke, United Kingdom)
(21).
Fecal egg counts. Fresh fecal samples (ca. 10 g each) were collected at 1- to
2-week intervals, by placing a collecting tray under the individual night cages.
The number of eggs per gram of feces was determined from each of three distinct
samples per animal, using the Percoll separation technique described recently
(M. Eberl, P. al-Sherbiny, S. Hagan, A. W. Ljubojevic, A. W. Thomas, and R. A.
Wilson, submitted for publication). This method, developed to allow accurate
measurements of fecal egg numbers, was far more sensitive than the conven-
tional Kato-Katz smear technique (34) and capable of detecting very low num-
bers of eggs per gram of feces. It proved necessary to take account of the
variation in fecal consistency resulting from the occurrence of schistosome-
induced diarrhea in some animals, which diluted the concentration of eggs. From
week 15 to 29 p.c., at approximately 2-week intervals, the chimpanzees were
retained in their individual night cages for 19 h to determine the total fecal
output from each; this allowed an estimation of the total egg output per day per
chimpanzee. Levels of vaccine-induced protection were calculated as the reduc-
tion in eggs per day in vaccinated chimpanzees compared to control animals.
Blood sampling and isolation of PBMC. At regular time points, 5 ml of
peripheral blood was obtained from each chimpanzee for the preparation of
serum, which was aliquoted and stored at 280°C until use. At most sampling
times, an additional 70 ml of blood was obtained for isolation of peripheral blood
mononuclear cells (PBMC). Cells were recovered by centrifugation over LSM
medium (ICN Biomedicals, Zoetermeer, The Netherlands) for 30 min at 900 3
g. The lymphocytes were washed twice with RPMI-1640 medium supplemented
with 2 mM L-glutamine and gentamicin (50 mg/ml). Purified PBMC were ad-
justed to a concentration of 107/ml, frozen in medium containing 10% dimethyl
sulfoxide–20% heat-inactivated human serum (Bloedbank Leiden-Haaglanden,
Sanguin Foundation, Leiden, The Netherlands), and stored at 2140°C until use.
Blood chemistry markers, hematocrit, leukocytosis, and peripheral blood eosin-
ophilia were analyzed using routine methods at the diagnostic laboratory of a
regional hospital (Diagnostic Center, Samenwerkingsverband Sociale Zekerheid
Delft, Delft, The Netherlands).
Circulating antigen levels. Serum samples were pretreated with trichloroacetic
acid to precipitate and remove interfering proteins and dissociate immune com-
plexes; soluble circulating anodic antigens (CAA) and CCA were then detected
by sandwich enzyme-linked immunosorbent assay (ELISA) using specific mono-
clonal antibodies (17, 18).
PBMC stimulation assays. All PBMC samples were assayed simultaneously, to
allow direct comparison between individual chimpanzees and between different
sampling time points. PBMC were thawed and washed twice in RPMI-1640
supplemented with 2 mM L-glutamine, gentamicin (50 mg/ml), and 10% fetal calf
serum (Life Technologies). Cultures were set up in triplicate in 96-well plates at
a density of 2 3 105 PBMC per well, in a final volume of 100 ml for proliferation
assays, or 200 ml for cytokine analysis. Cells were incubated at 37°C in 5% CO2
in medium alone or in the presence of a 10-mg/ml concentration of each antigen
preparation. Supernatants were removed after 72 h, and gamma interferon
(IFN-g), interleukin-4 (IL-4), IL-5, and IL-10 were detected by corresponding
two-site human cytokine ELISA kits, validated for determination of chimpanzee
cytokines (U-CyTech bv, Utrecht University, Utrecht, The Netherlands). Plates
for proliferation assays were pulsed after 96 h with 92.5 kBq of [3H]thymidine per
well (Amersham Pharmacia, Roosendaal, The Netherlands) for an additional
18 h and subsequently harvested on filters. The filters were baked for 1 h at 80°C,
and tritium incorporation was measured on a Packard Matrix 9600 helium
counter.
Antibody levels. Microtiter plates were coated overnight at 4°C with SWAP
(2.5 mg/ml), SEA (0.5 mg/ml), or SmE16 (0.2 mg/ml), diluted in phosphate-
buffered saline (23). The plates were washed five times with 10 mM Tris-HCl (pH
8.0)–150 mM NaCl–0.05% Tween 20 (TBST) and blocked with 3% bovine serum
albumin (BSA) (Sigma) in TBST for 1 h at 37°C. Sera were diluted 1:500 in 0.5%
BSA–TBST for detection of SmE16-specific antibodies, 1:1,500 for SWAP, and
1:20,000 for SEA, and the plates were incubated for 2 h at 37°C. After five
washes, the wells were probed for 1 h at 37°C with alkaline phosphatase-labeled
goat anti-human immunoglobulin G (IgG) or goat anti-human IgM (Biosource,
Etten-Leur, The Netherlands) diluted 1:5,000 in 0.5% BSA–TBST. After five
further washes, BluePhos Microwell substrate solution (Kirkegaard & Perry
Laboratories, Dynex Technologies, Billingshurst, United Kingdom) was added to
each well. Absorbance was quantified at 630 nm using a Dynatech MR500
ELISA reader.
Statistical analysis. A hierarchical analysis of variance (ANOVA) (59) was
used to test for significant variation in egg output at the following levels: (i)
average variation among fecal samples from the same animal, (ii) average vari-
ation among animals within each group, and (iii) differences between group
means. The error used for each level of variance was the mean square for the
next significant level down the hierarchy. Significance of differences in CCA
levels between the two groups was tested by two-tailed Student’s t tests for
unequal variance.
RESULTS
Vaccination results in a lower fecal egg output. In order to
monitor the time course of infection and to provide an esti-
mate of the parasite burden in the chimpanzees, fecal samples
were analyzed starting at week 4 p.c. The first schistosome eggs
were detectable at day 35 p.c. in one chimpanzee (V1) and at
day 40 p.c. in the remaining animals (Fig. 1). Fecal egg counts
reached their maximum at week 10 to 15 p.c., paradoxically
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somewhat earlier in the vaccinated animals than in the control
animals, and remained relatively stable throughout the infec-
tion, with the exception of V1. After chemotherapy, the egg
counts dropped immediately, and two to three sampling points
later no eggs were detectable, proving successful elimination of
parasites in all chimpanzees.
When egg output was determined on a per-day basis (i.e.,
over 19 h), a lower level was observed in vaccinated animals
than in the control animals (Table 1). The observed fluctua-
tions in numbers of eggs detected at the different sampling
times most likely reflect variations in the daily feces production
(data not shown), rather than showing temporary changes in
worm fecundity or excretion efficiency. Since the egg output
during chronic infection with S. mansoni is considered reason-
ably stable in human patients (2) and in chimpanzees (refer-
ence 55 and Fig. 1), it was subjected to an ANOVA using all
data available between week 15 p.c. (i.e., after the acute phase)
and the time of chemotherapy. Table 2 shows that there was,
on average, significant variation among the fecal samples from
the same animal, over and above the average level of variation
among the three replicate subsamples of each fecal sample.
There was no significant animal-to-animal variation within a
group above that attributable to the variation among the fecal
samples. However, there was variation between the two groups
over and above that at the levels of fecal samples and animals
within groups; the average egg output of the vaccinated group
was 38.4% less than that of the control group.
Vaccination results in lower CCA levels. As a second corre-
late of worm burden, we tested serum samples for the presence
of circulating schistosome antigens. Both CAA and CCA be-
came apparent by week 3 p.c., coincident with the acquisition
of blood feeding by the developing larvae. In four animals,
there was a good correlation between CAA levels and fecal egg
counts, with maximum values of ca. 250 to 500 ng/ml. However,
V1 had higher CAA levels and C3 had very much lower CAA
levels than anticipated from their respective egg counts (data
not shown). As a consequence, the mean CAA levels in the two
TABLE 1. Analysis of total fecal egg output per daya
Wk p.c.
Avg egg output 6 SEM
Control groupb Vaccinated groupb
15 126,398 6 28,644 91,806 6 28,995
17 66,644 6 9,591 59,803 6 14,646
21 94,634 6 7,477 21,563 6 1,217
22 88,657 6 33,044 36,624 6 4,618
24 126,490 6 26,350 69,091 6 38,669
26 136,202 6 9,220 114,803 6 3,840
Øc 106,504 6 15,759 65,615 6 19,887
a For statistical analysis, see Table 2.
b Average total egg output for each group 6 SEM from three fecal samples
analyzed per animal.
c Average fecal egg output per group between week 15 and week 26 p.c.
(protection level, 38.4%).
FIG. 1. Fecal egg burdens. Data shown represent means and SEM (error bars) from three fecal samples taken per time point. Symbols:
triangles, date of treatment with praziquantel; horizontal bars, period over which the protection level was calculated from daily egg output (Table
1). Abbreviations: C, control animals; V, vaccinated animals.
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groups were not markedly different. In contrast, from week
12 p.c. onwards, CCA levels in the controls were about twice
those in the vaccinated chimpanzees (Fig. 2). Calculation of
average CCA levels over the same period during which total
fecal egg output was estimated gave values (means 6 standard
errors of the means [SEM]) of 34.3 6 2.8 ng/ml for the controls
and 18.4 6 1.3 ng/ml for the vaccinated group. This corre-
sponds to a reduction of 46.3% (P , 0.01) and is remarkably
similar to the reduction in fecal egg output (Table 1). Impor-
tantly, CAA and CCA values returned to baseline by week
45 p.c., due to rapid clearance after chemotherapy.
Vaccinated chimpanzees experience diminished clinical
signs of disease. Repeated vaccination did not result in any
detectable changes of the general health status. However, after
challenge infection, general malaise was observed in both
groups, and loss of appetite was observed mainly in the con-
trols around weeks 7 and 8 p.c. (at the peak acute stage); no
fever was detected in either group. After week 7 to 11 p.c.,
chimpanzees C1, V1, and V2 showed signs of diarrhea and
developed bloody feces over the following weeks. The other
three chimpanzees, C2, C3, and V3, experienced only occa-
sional mild diarrhea. During the chronic infection there were
no problems with appetite, but general malaise was evident
during periods of heavy diarrhea. In order to ease the symp-
toms, C1 and V1 were treated once with an antispasmodic
drug, butylscopolaminebromide (Buscopan; Boehringer Ingel-
heim, Alkmaar, The Netherlands). No differences in intestinal
pathology were observed between the two groups; a detailed
examination will be published elsewhere (J. A. M. Langermans
et al., unpublished data). After chemotherapy with praziquan-
tel, the chimpanzees showed a complete recovery. From infec-
tion until treatment, all individuals showed increases in body
weight that were similar to data from naı¨ve male animals of
comparable age in the colony, over the same period (data not
shown).
Hematological tests included determination of total leuko-
cyte counts, percentage eosinophilia, and hematocrit. The
mean values for both groups were similar in the naı¨ve animals
prior to vaccination or challenge. However, at the height of
acute infection (week 7 to 8 p.c.), vaccinated animals had
virtually unchanged leukocyte and eosinophil levels, whereas in
control animals, the total leukocyte number was significantly
elevated (Fig. 3A), and a pronounced eosinophilia was present
(Fig. 3B). Both control leukocyte numbers and eosinophil
counts returned to almost normal levels by week 14 p.c. Sur-
prisingly, from that time point on, vaccinated chimpanzees had
slightly elevated leukocyte numbers throughout the chronic
stage, compared to controls. Hematocrit dropped in both
groups after challenge infection and stayed below the naı¨ve
level at least until week 30 p.c., with controls having lower
values than vaccinated animals (Fig. 3C). Blood chemistry pro-
files were determined for alkaline phosphatase, lactate dehy-
drogenase, bilirubin, and gamma-glutamyl transferase (g-GT).
No differences between the two groups were found for the first
three markers, which stayed within the normal range for chim-
panzees throughout the experiment (data not shown). How-
ever, in control animals the values of g-GT showed an increase
from week 9 p.c., up to 2.5 times the normal level, and re-
mained elevated thereafter, while no significant increase was
observed in the vaccinated group (Fig. 3D). In contrast, Dopp-
ler ultrasonographic examination of individual chimpanzees
did not reveal any detectable differences in liver pathology
between the two groups (data not shown).
Vaccination induces a strong cellular immune response,
which is down-regulated after challenge infection. After the
first exposure to attenuated parasites, PBMC from the vacci-
nated chimpanzees showed a detectable proliferative response
to SWAP and to SEA, which was subsequently boosted by
further immunizations (Fig. 4A, D). The maximum cellular
reactivity coincided with the time of challenge infection, after
which the antigen-specific cell proliferation dropped rapidly
and then remained at a low but constant level. Unexpectedly,
the vaccinated chimpanzees exhibited no prominent memory
response after challenge. In the infected control animals,
PBMC proliferation values peaked at week 6 p.c., at the start
of the acute phase of infection. These maximum levels were
lower than the peak response in the vaccinated chimpanzees,
which most likely reflected the differences in the preceding
antigenic loads in the two groups (3 3 9,000 attenuated cer-
cariae versus 2,000 normal cercariae).
A type 1 cytokine response is induced by the first vaccina-
tion, and a type 2 response is induced by further vaccinations.
The vaccinated animals mounted a type 1 cytokine response
FIG. 2. CCAs. Sera were obtained at regular intervals and assayed
for CCA. Data shown represent means and SEM (error bars) from
three individuals. Symbols: horizontal bar, period over which the pro-
tection level was calculated; open circles, control group; closed circles,
vaccinated group.
TABLE 2. Statistical analysis of total fecal egg output per daya
Source df SS MS (error) Fb
Groups 1 44,479.5694 44,479.5694 (3) 8.68pp
Animals in groups 4 26,516.7487 6,629.1872 (3) 1.29 NS
Fecal samples from
animals
30 153,753.6108 5,125.1204 (4) 4.25ppp
Replicates in fecal
samples
72 86,832.4025 1,206.0056
Total 107 311,579.3312
a df, degrees of freedom; SS, sum of squares; MS, mean square; F, variance
ratio.
b ANOVA for data from weeks 15 and 26 p.c.: pp, P , 0.01; ppp, P , 0.001;
NS, P . 0.05.
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after the first vaccination, as judged by the rapid increase in
IFN-g in SWAP- and SEA-stimulated PBMC cultures; produc-
tion was down-regulated after subsequent vaccinations and was
hardly detectable after challenge infection (Fig. 4B and E).
PBMC from the control chimpanzees produced IFN-g in the
presence of SWAP and SEA only at week 6 p.c. and negligible
amounts at later time points, after progression to the chronic
disease state. In comparison with the pattern of IFN-g, the
levels of the type 2 cytokine IL-5 increased gradually with each
vaccination and peaked at the time of challenge (Fig. 4C and
F). They decreased within a few weeks p.c. but remained ele-
vated throughout the whole course of the challenge infection,
with higher values for SEA than SWAP stimulation. Thus, IL-5
but not IFN-g production mirrored the pattern of PBMC pro-
liferation. In the control group, IL-5 remained elevated after a
dramatic rise at week 6 p.c., with higher levels after culture in
the presence of SEA than SWAP; after week 25 p.c., the
profiles were similar in both groups. Levels of IL-4 were lower
but generally followed the pattern of IL-5 (data not shown).
Only antigens released by larvae induce a secondary type 1
cytokine response after challenge infection. Examination of
other antigen preparations revealed that the overall PBMC
response after stimulation with lung-stage antigens (soluble
larval antigens) was almost identical to the data obtained with
SWAP (data not shown). In addition, the response to antigens
secreted by live eggs (ESP) matched closely the proliferation
and cytokine pattern observed in the presence of SEA (data
not shown). In contrast, antigens released by freshly trans-
formed schistosomula (0–3hRAP) induced a prominent p.c.
IFN-g response by PBMC from the vaccinated chimpanzees
(Fig. 4H). This secondary IFN-g secretion was at an earlier
time point than the first appearance of IFN-g in the control
group, peaking at week 4 p.c. In contrast to IFN-g, neither the
PBMC proliferation nor the IL-5 response in the presence of
0–3hRAP showed any obvious difference to the other antigen
preparations (Fig. 4G and I).
Vaccination elicits production of the regulatory cytokine
IL-10. In the vaccinated group, stimulation of PBMC with
SWAP and SEA led to an early increase of IL-10, in parallel
with the elevated amounts of IFN-g, but showed a peak at
much higher levels shortly after the maximum IL-5 response
(Fig. 5). In both groups, SEA induced more IL-10 than SWAP.
FIG. 3. Clinical parameters. Total leukocyte numbers (A), eosinophil counts (B), hematocrits (C), and levels of serum g-GT (D) were
determined in the naı¨ve chimpanzees before any treatment (depicted as week 0) and at regular time points after challenge. Data shown represent
means and SEM (error bars) from three individuals; data for g-GT are calculated as fold increase above the values for naı¨ve chimpanzees (range,
22 to 46 U/ml). Symbols: open circles, control group; closed circles, vaccinated group.
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Chemotherapy also seemingly had an influence on the IL-10
secretion of PBMC, since the levels after treatment were sig-
nificantly elevated in the three vaccinated chimpanzees (week
44 p.c.) as well as in one control animal (C1; week 35 p.c.).
Vaccination induces high titers of IgM and IgG antibodies
against parasite antigens. In the vaccinated group, SWAP-
and SEA-reactive IgM antibody titers increased after vaccina-
tion and were at a peak at the time of challenge infection (Fig.
6A and B); IgG titers peaked very shortly afterwards (Fig. 6D
and E). However, analogous to the cellular response, IgM and
IgG antibody titers declined after challenge infection and only
recovered after the onset of the acute stage of the infection.
SWAP- and SEA-reactive IgM titers decayed with time, where-
as IgG remained at constant levels throughout the chronic
stage of the infection. In the controls, IgM antibodies against
SWAP and SEA were detectable from week 4 to 5 p.c. on-
wards, followed by IgG antibodies after week 5 to 6 p.c. IgG
titers finally reached a plateau at the same levels as in the
vaccinated group, but with SEA-reactive antibodies showing a
steeper rise. IgM titers against both worm and egg antigens
declined gradually, as seen in the vaccinated chimpanzees. For
IgM, comparison of the two groups revealed that SWAP-reac-
tive levels were similar, but those for SEA were much greater
in the controls.
Vaccinated chimpanzees have lower antibody titers against
the egg-specific antigen SmE16. Repeated exposure to atten-
uated cercariae led to a rapid development of both SWAP- and
SEA-reactive IgG and IgM antibodies in the absence of para-
site maturation or oviposition, implying marked cross-reactivity
between larval, adult worm, and egg antigenic epitopes. In con-
trast, in both groups, IgG antibodies against the egg-specific cal-
cium-binding protein SmE16 were not detectable before week 6
to 7 p.c., confirming the stage specificity of the protein (Fig. 6F).
Most importantly, the control chimpanzees produced much
higher levels of SmE16-specific IgG antibodies than the vacci-
FIG. 4. PBMC response to schistosome antigens. PBMC were cultured in the presence of SWAP (A to C), SEA (D to F), and 0–3hRAP (G
to I) and assayed for thymidine incorporation (A, D, and G), secretion of IFN-g (B, E, and H), and IL-5 (C, F, and I). Data shown represent means
and SEM (error bars) from three individuals. Symbols: open circles, control group; closed circles, vaccinated group; triangles, vaccinations and
challenge. Due to limitations of the material available, 0–3hRAP was only tested until week 14 p.c.
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nated individuals. SmE16-specific IgM levels were generally
low, but also appeared to be higher in the controls (Fig. 6C).
DISCUSSION
Our study is the first to report the successful use of an
attenuated vaccine to protect chimpanzees against a humano-
pathogenic helminth, as earlier attempts with Schistosoma ja-
ponicum (30) or Onchocerca volvulus vaccines failed (50). The
beneficial effect of prior exposure to the RA vaccine on the
outcome of subsequent S. mansoni challenge infection can
be deduced from parasitological, immunological, and clini-
cal data. We observed a significant reduction in serum CCA
levels and in the egg output of the vaccinated chimpanzees and
significantly lower titers of egg antigen-specific antibodies,
compared to the controls. Additionally, previous vaccination
ameliorated the signs of the acute immune response in the
vaccinated animals and reduced morbidity during the acute
and early chronic infection, as judged by serum g-GT levels,
leukocytosis, eosinophilia, and hematocrit. This is also the first
longitudinal study to monitor the development of the immune
response from infection through the acute and chronic phases
of the disease, using up-to-date assays, in the host most closely
related to humans. All clinical data available on human im-
mune responses and pathology are from cross-sectional stud-
ies, due to the requirement of administering chemotherapy
upon diagnosis.
Exposure of chimpanzees to the RA vaccine induced a
strong cellular proliferative response to parasite antigens, the
intensity of which was enhanced by each additional vaccina-
tion, as previously observed in baboons (70). The initial type 1
bias, evidenced by IFN-g production, was not boosted by the
repeat vaccinations that augmented IL-4 and IL-5 production,
indicative of a type 2 response. This is consistent with anal-
ogous data obtained with multiply vaccinated mice (13).
Although a Th1-Th2 switch observed in schistosome-infected
mice has been associated with the onset of egg production (47),
our data confirm that multiple exposures to larval antigens are
clearly a sufficient trigger (13). Indeed, a marked degree of
cross-reactivity is evident between the several antigen prepa-
rations used for lymphocyte stimulation, suggesting that it is
not the parasite stage but rather repeated exposures to com-
mon antigenic epitopes that are responsible. Challenge of vac-
cinated chimpanzees coincided with the peak proliferative re-
sponse, which unexpectedly decayed rapidly thereafter, giving
little evidence for a subsequent memory reaction. Down-mod-
ulation of cellular immune responses after cercarial challenge
has also been reported in mice (48) and baboons (70) exposed
to the RA vaccine; in the former study IL-10 induction was
proposed as the causative factor. In the present investigation,
we observed IL-10 production rising gradually and peaking
shortly after challenge, making this cytokine a good candidate
for down-regulation of the proliferative and type 2 response
(60) but not the early type 1 response (unless IFN-g produc-
tion is inhibited at much lower IL-10 concentrations than those
at which IL-5 is inhibited). This begs the question as to whether
other cytokines, such as transforming growth factor b (19, 45),
or cellular processes, such as apoptosis (12), might be involved.
It needs to be emphasized that this down-modulation of im-
mune responses occurred in vaccinated chimpanzees before
oviposition. Nevertheless, in humans with intestinal schistoso-
miasis, IL-10 is secreted by PBMC, particularly in response to
egg antigens (5, 37, 67), which were also the most efficient in-
ducers in our own study. A major task is to identify the cross-
reactive components responsible for driving IL-10 production,
with glycan epitopes being likely candidates (62).
Exposure of the control chimpanzees to normal challenge
cercariae elicited only low proliferative responses and negli-
gible cytokine production by antigen-stimulated PBMC in
the ensuing weeks. It is unclear to what extent this reflects
the lower parasite dose (2,000 cercariae) or immunogenicity of
normal larvae, compared to the vaccinating situation. Only
after oviposition was there a marked elevation in cellular re-
activity, which signaled the start of the acute stage, with the
simultaneous secretion of IFN-g and IL-5 by PBMC; the egg
antigen-driven type 2 response quickly came to dominate.
There are parallels here with human schistosomiasis, in which
PBMC sampled from patients at the acute stage of the disease
show strong proliferative responses and IFN-g secretion (37,
41). In contrast, PBMC from patients with chronic intestinal
schistosomiasis secrete hardly any IFN-g (63) but secrete sig-
nificant amounts of IL-5 (5, 39).
FIG. 5. IL-10 response to schistosome antigens. PBMC were cul-
tured in the presence of SWAP (A) and SEA (B) and were assayed for
IL-10. Data shown represent means and SEM (error bars) from three
individuals. Symbols: open circles, control group; closed circles, vacci-
nated group; asterisks, IL-10 values for one control (C1) at week
35 p.c., which were almost 10-fold higher than for the other animals,
and therefore excluded from the calculation of average IL-10 levels.
Data at week 45 p.c. are from two animals.
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The down-modulatory transition from the acute to the
chronic stage appeared to be complete by week 12 to 14
postexposure, depending on the immunological parameter se-
lected. Thereafter, the proliferative and type 2 cytokine re-
sponses remained at a low but detectable level. Termination of
the chronic phase by chemotherapy, bringing about a massive
release of somatic antigens, boosted production of type 2 but
not type 1 cytokines. The vaccinated animals showed a strik-
ingly different response with little or no evidence of an acute
stage after the start of egg production. In that respect, the
vaccine was clearly host protective. Measurement of biochem-
ical and hematological parameters over the acute and early
chronic stages provided further evidence for this protective
effect. A drop in hematocrit is used as an indicator of blood
loss and overall morbidity in schistosomiasis patients (24).
Higher hematocrits of vaccinated chimpanzees compared to
controls may be a consequence of a lower worm burden and/
or less intestinal inflammation. Furthermore, the vaccinated
chimpanzees did not exhibit leukocytosis or eosinophilia,
which are hallmarks of acute schistosomiasis in humans (54).
These clinical features were very evident in the control group
and have been reported in earlier chimpanzee studies (55, 65).
Serum g-GT is a marker for hepatocellular injury, with in-
creased levels observed in human patients with severe peripor-
tal fibrosis, hepatosplenomegaly, and ascites (32, 38). How-
ever, we observed elevated levels in control animals from the
acute stage onwards, but not in vaccinated chimpanzees. Thus,
our observation may reflect early liver tissue damage (e.g.,
from egg-secreted proteases [6]) due in part to the greater egg
deposition in the control group but also due to the apparent
FIG. 6. Antibody response to schistosome antigens. Sera were obtained at regular intervals and assayed for IgM (A to C) and IgG (D to F)
antibodies directed against SWAP (A and D), SEA (B and E), and SmE16 (C and F). Data shown represent means and SEM (error bars) from
three individuals. Symbols: open circles, control group; closed circles, vaccinated group.
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lack of an acute inflammatory phase of infection in the vac-
cinated group. To our knowledge, presence of g-GT during
acute schistosomiasis has only been reported before in calves
experimentally infected with Schistosoma bovis (36). It can be
assumed that due to the experimental challenge conditions in
this and in our own study, synchronized egg deposition oc-
curred, as opposed to the more gradual incremental egg dep-
osition resulting from trickle infections. Alkaline phosphatase
as a marker for biliary obstruction and lactate dehydrogenase
and bilirubin as markers for general liver pathology may be-
come more pronounced later during chronic disease (4). In this
respect, the lack of any ultrasonographically detectable differ-
ences between the two groups was not surprising given the
limited duration of the present study, which was too short to
allow for development of significant pipe stem fibrosis or portal
hypertension (55, 65).
The RA vaccine also elicited a strong humoral immune
response in the chimpanzees. Egg antigens were the most po-
tent inducers of antibodies compared to other preparations
(note the lower antigen concentrations and higher serum di-
lutions used in the ELISA protocol). The recognition of SEA
by sera before challenge cannot be attributed to breakthrough
of vaccinating parasites since eggs were not detectable in the
feces before week 5 to 6 p.c., nor IgG antibodies against the
stage-specific egg antigen SmE16 in the serum before week 6
to 7 p.c. Moreover, levels of circulating antigens were not
elevated before challenge. The most likely explanation is that
antigenic epitopes, such as common housekeeping and struc-
tural proteins, or glycan epitopes are shared between larvae,
adult worms, and eggs. Glycan epitopes have already been
demonstrated on cercariae and eggs (23, 46). As with cellular
immunity, challenge of vaccinated chimpanzees coincided with
a peak in both IgM and IgG titers, which then declined for 5 to
6 weeks, indicating that the 2,000 normal larvae were not
providing a significant boost to the humoral response. This
trend was reversed by oviposition, transiently for IgM but more
permanently for IgG, indicating the importance of eggs in the
maintenance of high antischistosome titers, and the relatively
weaker response to adult worm antigens (23); similar observa-
tions on egg-specific antibodies have been made in chronically
infected humans (10). The profile of antibody levels in the
control chimpanzees also revealed little or no reactivity until
after oviposition. The most notable differences between the
two groups were in titers of SEA-specific IgM and SmE16-
specific IgM and IgG. This may imply a disparity in the anti-
genic stimulus between control and vaccinated animals due to
a difference in worm burden or fecundity, and hence a differ-
ence in egg production. In the case of SmE16, the difference
cannot be ascribed to desensitization by vaccination, as the
antigen is egg specific (42).
For estimating fecal egg output, a novel gradient technique
was developed that proved to have a high sensitivity and was
excellent for dealing with loose stools (Eberl et al., submitted).
The significantly lower daily egg release from vaccinated chim-
panzees is a convincing result, given the small sample size and
absence of precedents for experimental design; this is sup-
ported by the close match of the estimates of egg burdens with
the CCA levels throughout the whole course of the study (49).
The nearest comparisons are investigations involving triple
exposures of vervets and baboons to the RA vaccine, in which
protection levels of approximately 50% have been reported,
based on perfusion data (3, 69, 70). In both these simian hosts,
a good correlation was obtained between anti-worm IgG titers
at the end of the vaccination period and the worm burden of
individual animals. Our data from chimpanzees, with a domi-
nant type 2 response and high antibody titers at the time of
challenge, also point to an antibody-mediated effector mecha-
nism. Nevertheless, the operation of an additional type 1-me-
diated mechanism was indicated by the secondary production
of IFN-g by PBMC in response to antigens released by larvae.
Cell-mediated protection appears to be most effective follow-
ing a single exposure of mice to the RA vaccine, where IFN-g
is dominant (57, 58). However, in the murine host, multiple
vaccinations fail to boost cell-mediated immunity but progres-
sively enhance the humoral arm of the protective response (13,
31). Further evidence for the importance of type 2-mediated
effector mechanisms comes from human patients, where a cor-
relation exists between IL-4 and IL-5 production by PBMC
and resistance to reinfection after drug treatment (40, 53). It
has to be noted that in humans, IgE and IgA antibodies have
been postulated to participate in protective immunity (20, 26,
27). Unfortunately, due to limitations of material, assays for
parasite-specific IgA or IgE could not be performed.
This intensive chimpanzee study also underlines the poten-
tial difficulties facing the evaluation of any schistosome vaccine
in a human population, not least in the indirect estimation of
worm burden by fecal egg output. A longitudinal sampling
regimen was required to establish the validity of a 38% pro-
tection level in the chimpanzees. Thus, a vaccine would need to
generate a strong protection, with a large differential in egg
output between test and placebo groups, to demonstrate effi-
cacy. Conversely, CCA levels and the various clinical parame-
ters of protection were easier to evaluate and merit serious
consideration for inclusion in future vaccine trials. Moreover,
the differences in antibody responses between test and control
groups, illustrated by the egg antigen data, deserve attention.
Our study highlights a need for a range of stage-specific re-
combinant antigen markers in addition to SmE16 in eggs. De-
spite the manifold problems facing the development and test-
ing of a schistosome vaccine, we are cautiously optimistic. That
the RA vaccine generates a significant protection in prepubes-
cent chimpanzees gives us confidence to continue the task of
converting it to a recombinant antigen formulation (21, 22, 28,
29), as the human target group for vaccination programs will
mainly be children.
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